ASH 2020 | Predicting cytopenia in lymphoma patients treated with axi-cel
Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses a study aiming to determine the rate of cytopenia in patients with large cell lymphoma (LCL) who have been treated with axicabtagene ciloleucel (axi-cel). An in-depth analysis of patient data was conducted, focusing on pre- and post- axi-cel treatment factors associated with cytopenia. The findings of this study show that severe cytopenia is common after axi-cel, especially in patients in need of subsequent therapies. Pre-CAR-T cytopenia and transfusion needs as well as post-CAR-T steroid use were identified as potential predictors of day 30 severe cytopenia in patients with LCL undergoing axi-cel treatment. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
